Heart Attack News and Research

RSS

GSK supports AHA policy statement on smokeless tobacco products

GlaxoSmithKline (GSK) Consumer Healthcare, a leader in helping smokers quit and the marketer of nicotine replacement therapy (NRT) products, including Nicorette and NicoDerm CQ, supports the findings of the American Heart Association (AHA) policy statement regarding smokeless tobacco products.

28 Sep 2010

Bayer’s new oral contraceptive receives FDA approval

Bayer HealthCare Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration has approved a new oral contraceptive, Beyaz (drospirenone / ethinyl estradiol / levomefolate calcium tablets and levomefolate calcium tablets).

28 Sep 2010

DecImmune Therapeutics receives funds to improve ischemia reperfusion injury outcomes

DecImmune Therapeutics announced today that it has received a $1 million equity investment from Astellas Venture Management and has additionally been awarded $2.2 million in Phase II SBIR funding from the National Institutes of Health.

28 Sep 2010

Disparities in cardiac care begin when patients arrive at hospital emergency rooms: Study

The well-documented disparities in cardiac care may begin almost as soon as patients arrive at hospital emergency rooms. In a study published in Academic Emergency Medicine, Massachusetts General Hospital researchers report that African-American and Hispanic patients assessed for chest pain were less likely than white patients to be categorized as requiring immediate care, despite a lack of significant differences in symptoms.

27 Sep 2010

Researchers find no link between dialysis treatments and cardiac symptoms

Dialysis treatments do not affect the heart health of kidney disease patients who have had a heart attack, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology (CJASN). Since cardiovascular disease is the most common cause of death in kidney disease patients, the findings are good news for individuals who need the treatments.

27 Sep 2010

Boston releases HORIZONS-AMI trial data

Angiotech Pharmaceuticals, Inc. announced that its corporate partner, Boston Scientific Corporation, has released three-year follow-up data from the HORIZONS-AMI trial.

27 Sep 2010

FDA, European regulators restrict Avandia use

The Food and Drug Administration and European regulators said they were taking action on Avandia, made by GlaxoSmithKline PLC, because of data tying it to increased risk of heart attacks.

27 Sep 2010

NYU Langone Medical Center announces presentations at TCT 2010 scientific symposium

Researchers from the Cardiac & Vascular Institute at NYU Langone Medical Center will present at the Transcatheter Cardiovascular Therapeutics (TCT) 2010 scientific symposium on September 21-25, 2010 in Washington, DC.

24 Sep 2010

Malnutrition, inflammation complicate blood cholesterol readings in CKD patients

To understand the health effects of high cholesterol levels, doctors first need to assess malnutrition and inflammation status in their chronic kidney disease (CKD) patients, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN).

24 Sep 2010

Takeda underscores commitment to ACTOS following FDA and EMA announcements for rosiglitazone

Following today’s announcements by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for rosiglitazone in the U.S. and Europe, Takeda Pharmaceuticals North America, Inc. and Takeda Pharmaceuticals Europe Limited underscore the company’s commitment to ACTOS® (pioglitazone HCl) and ACTOS-containing medications, and to the millions of people living with type 2 diabetes.

24 Sep 2010

Technologic innovation — Telephones! — could save health system money

Health-coaching more patients over the phone could help save the system money according to a study published Wednesday in the New England Journal of Medicine and noticed by the Wall Street Journal's Health Blog. "Typically this kind of care management, as it's called, is offered to people who have trouble managing their chronic conditions or who are facing a big treatment decision — such as surgery or medical management for lower back pain.

24 Sep 2010

Avandia restricted by the FDA and EMEA

The U.S. Food and Drugs Administration (FDA) has restricted the use of the controversial diabetes drug Avandia (rosiglitazone) due to its propensity to increase cardiovascular disease risk.

24 Sep 2010

Athersys presents MultiStem phase I study results at TCT Conference

Athersys, Inc. announced at its presentation at the Transvascular Cardiovascular Therapeutics (TCT) Conference held in Washington, D.C., updated results from its phase I clinical trial of MultiStem, its allogeneic cell therapy product, administered to individuals following acute myocardial infarction (AMI).

23 Sep 2010

Erasmus Medical Center Professor to present LEADERS trial result at TCT symposium

Three-year data from the prospective, randomized LEADERS trial demonstrate the equivalence of a biolimus A9-eluting stent with a biodegradable polymer vs. a sirolimus-eluting stent with a durable polymer. The results will be presented at the 22nd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation.

23 Sep 2010

Vascular Disease Foundation honors UCSD professor with President's Award for Vision

The Vascular Disease Foundation has awarded Michael Criqui, MD, MPH, professor and chief of the Division of Preventive Medicine in the Department of Family and Preventive Medicine at the University of California, San Diego, one of its highest honors, the President's Award for Vision. The award was presented at the VDF's annual meeting in Alexandria, Virginia on September 20.

22 Sep 2010

Paper calls for revision of STEMI guidelines around oxygen therapy

The European Society of Cardiology welcomes a paper published today in the Journal of the American College of Cardiology highlighting concerns over the use of oxygen therapy during MI in patients with normal oxygen levels. The publication adds to calls for revision of the STEMI guidelines around oxygen therapy and for a prospective, large scale randomised trials, issues that were both first raised in a Cochrane Review published in June.

22 Sep 2010

PROMUS Element Stent receives expanded indications approval for high-risk diabetic and AMI patient groups

Boston Scientific Corporation today announced that its PROMUS® Element™ Everolimus-Eluting Coronary Stent System has received CE Mark approval for use in patients with diabetes and those experiencing an acute myocardial infarction (AMI), or heart attack.

21 Sep 2010

Celera receives patent on KIF6 gene variant

Celera Corporation today announced that the United States Patent and Trademark Office has issued United States Patent 7,799,530 relating to methods of determining heart attack risk by detecting the KIF6 gene variant and reduction of such increased risk by statin therapy.

21 Sep 2010

New MTWA technology is integrated in Quinton Q-Stress cardiac stress systems

Cambridge Heart, Inc., a developer of noninvasive diagnostic tests for cardiac disease, today announced the launch of its Microvolt T-Wave Alternans (MTWA) technology as an integrated part of industry-leading cardiac stress test systems manufactured and distributed by Cardiac Science Corporation. The MTWA technology, which can predict a patient's risk of sudden cardiac arrest (SCA), is now being offered to new and existing users of Cardiac Science's Quinton Q-Stress cardiac stress systems.

21 Sep 2010

Paper highlights need for new studies and guidelines around oxygen therapy during MI

The European Society of Cardiology (ESC) welcomes a paper published today in the Journal of the American College of Cardiology (JACC )(1) highlighting concerns over the use of oxygen therapy during MI in patients with normal oxygen levels. The publication adds to calls for revision of the STEMI guidelines around oxygen therapy and for a prospective, large scale randomised trials, issues that were both first raised in a Cochrane Review published in June.

21 Sep 2010

Heart Attack News and Research

GSK supports AHA policy statement on smokeless tobacco products

Bayer’s new oral contraceptive receives FDA approval

DecImmune Therapeutics receives funds to improve ischemia reperfusion injury outcomes

Disparities in cardiac care begin when patients arrive at hospital emergency rooms: Study

Researchers find no link between dialysis treatments and cardiac symptoms

Boston releases HORIZONS-AMI trial data

FDA, European regulators restrict Avandia use

NYU Langone Medical Center announces presentations at TCT 2010 scientific symposium

Malnutrition, inflammation complicate blood cholesterol readings in CKD patients

Takeda underscores commitment to ACTOS following FDA and EMA announcements for rosiglitazone

Technologic innovation — Telephones! — could save health system money

Avandia restricted by the FDA and EMEA

Athersys presents MultiStem phase I study results at TCT Conference

Erasmus Medical Center Professor to present LEADERS trial result at TCT symposium

Vascular Disease Foundation honors UCSD professor with President's Award for Vision

Paper calls for revision of STEMI guidelines around oxygen therapy

PROMUS Element Stent receives expanded indications approval for high-risk diabetic and AMI patient groups

Celera receives patent on KIF6 gene variant

New MTWA technology is integrated in Quinton Q-Stress cardiac stress systems

Paper highlights need for new studies and guidelines around oxygen therapy during MI

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News